Abraxis Bioscience Inc. New Reports Operating Results (10-Q)
GuruFocus Updates (Free subscription) | 11/09/2009
By 10qk. Abraxis Bioscience Inc. New ( ABII ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
Abraxis BioScience, Inc.
Your search relates to more than one category
3Vote!
4Vote!
Abraxis BioScience Reports 2009 Third Quarter Financial Results
Business Wire (Free subscription) | 11/05/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009. As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)...
5Vote!
A doctor without borders
L. A. Times Dodgers Blog (Free subscription) | 11/22/2009
Abraxis BioScience Chairman Patrick Soon-Shiong is putting his billions to work to bridge the gap between science and medicine and to erase the disparities in healthcare between rich and poor. The gig: Billionaire chairman of drug developer Abraxis BioScience Inc. and philanthropist.
Explore : Business
4Vote!
ABRAXANE(R) Receives Orphan Drug Status For The Treatment Of Pancreatic Cancer And Stage IIB-IV Melanoma
Medical News Today (Free subscription) | 11/08/2009
Abraxis BioScience, Inc.
5Vote!
Abraxis opens expanded plant in Phoenix, expected to create 200 jobs
The Los Angeles Business (Free subscription) | 11/05/2009
Abraxis BioScience Inc., a Los Angeles maker of a chemotherapy drug that uses nanoparticles, is continuing its expansion in the Phoenix market.
Explore : Business
+Vote!
Abraxis opens expanded plant in Phoenix, expected to create 200 jobs
bizjournals (Free subscription) | 11/05/2009
Abraxis BioScience Inc., a Los Angeles-based maker of a chemotherapy drug that uses nanoparticles, is continuing its expansion in the Phoenix market.
Explore : Software
5Vote!
ABRAXANE® Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
Business Wire (Free subscription) | 11/05/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)...
4Vote!
Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona
Business Wire (Free subscription) | 11/05/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc. (NASDAQ:ABII), today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs. The new facility...
3Vote!
Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
StreetInsider.com News Articles (Free subscription) | 11/04/2009
The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session: Before Market Opens: Economics: 8:30am ET Employment Cost Index - no Street consensus Initial jobless claims - Street Sees 520K Continuing Claims - Street Sees 5.75M Earnings: Abiomed, Inc. (NASDAQ: ABMD) – consensus loss $0.21 Abraxis BioScience, Inc. (NASDAQ: ABII) –...